UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Summary

[ Back to Protocol Listing ]

[ Print this page ]

Protocol No.115523Principal InvestigatorFriedlander, Terence
PhaseII (Cancer Control)
Age GroupAdultScopeNational
Secondary Protocol No.ARN-509-002
TitleThe Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
Objective1. To compare the mean change in QOL as measured by total FACT-P score after 12 months of therapy with ARN-509 monotherapy compared with LHRHa monotherapy 2. To compare the mean change in QOL as measured by total FACT-P score after 12 months of therapy of ARN-509 + LHRHa vs. LHRHa monotherapy
Key EligibilityAge: 18+ * Male * Histologically proven adenocarcinoma of the prostate * No history of seizures or medical conditions which may lower seizure threshold
Applicable Disease SitesProstate
Drugs InvolvedARN-509
StatusOpen
Participating InstitutionsMt. Zion : Rebecca Cook
Oregon Health & Science University
University of Chicago
University of Washington
Eligibility Document115523_CTGovEligibility_NCT01790126.doc
ContactRebecca Cook Phone:415-885-7329
Pager:
Email:CookR@cc.ucsf.edu